Abstract | BACKGROUND: METHODS: A multicenter review of 1425 women with histopathologically confirmed EOC was performed. Comparisons were made between patients with documented beta-blocker use during chemotherapy and those without beta-blocker use. RESULTS: The median age of patients in the current study was 63 years (range, 21-93 years). The sample included 269 patients who received beta-blockers. Of those, 193 (71.7%) were receiving beta-1-adrenergic receptor selective agents, and the remaining patients were receiving nonselective beta antagonists. The primary indication for beta-blocker use was hypertension but also included arrhythmia and postmyocardial infarction management. For patients receiving any beta-blocker, the median overall survival (OS) was 47.8 months versus 42 months for nonusers (P =.04). The median OS based on beta-blocker receptor selectivity was 94.9 months for those receiving nonselective beta-blockers versus 38 months for those receiving beta-1-adrenergic receptor selective agents (P<.001). Hypertension was associated with decreased OS compared with no hypertension across all groups. However, even among patients with hypertension, a longer median OS was observed among users of a nonselective beta-blocker compared with nonusers (38.2 months vs 90 months; P<.001). CONCLUSIONS: Use of nonselective beta-blockers in patients with EOC was associated with longer OS. These findings may have implications for new therapeutic approaches. Cancer 2015;121:3435-43. © 2015 American Cancer Society.
|
Authors | Jack L Watkins, Premal H Thaker, Alpa M Nick, Lois M Ramondetta, Sanjeev Kumar, Diana L Urbauer, Koji Matsuo, Kathryn C Squires, Robert L Coleman, Susan K Lutgendorf, Pedro T Ramirez, Anil K Sood |
Journal | Cancer
(Cancer)
Vol. 121
Issue 19
Pg. 3444-51
(Oct 01 2015)
ISSN: 1097-0142 [Electronic] United States |
PMID | 26301456
(Publication Type: Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | © 2015 American Cancer Society. |
Chemical References |
- Adrenergic beta-Antagonists
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Aged
- Aged, 80 and over
- Disease-Free Survival
- Female
- Humans
- Middle Aged
- Ovarian Neoplasms
(drug therapy, mortality)
- Prognosis
- Retrospective Studies
- Survival Analysis
- Young Adult
|